1 study on PE-22-28 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Simple Peptide | 3 | 99.79% | View COA → |
| Pure Peptide Labs LLC | 3 | 99.79% | View COA → |
| Peptide Technologies | 2 | 99.93% | View COA → |
| (unknown) | 2 | 99.88% | View COA → |
| Rejuvenate Peptides | 2 | 99.86% | View COA → |
| Peptaris | 2 | 99.79% | View COA → |
| Uther Peptide | 2 | 99.78% | View COA → |
| Unknown vendor (review) | 2 | 99.75% | View COA → |
Recent certificates: #39754 (99.65%) · #51582 (99.76%) · #63208 (99.754%) · #31563 (97.22%) · #48801 (99.62%) · #48684 (99.72%)
Manufacturers with published third-party certificates of analysis for PE-22-28. Open a vendor to see every batch we've verified.
This research provides fundamental insights into the mechanisms governing autophagy, a process vital for cellular health and implicated in numerous diseases, including cancer, neurodegeneration, and infectious disease…
Free, no account — handy when you're working with PE-22-28.